Citrus flavonoid blend targets prediabetes

Jennifer Grebow
Jennifer Grebow

Jennifer Grebow is the editor-in-chief of Nutritional Outlook, an award-winning media-content provider in the dietary supplement and natural products market. Nutritional Outlook, an MJH Life Sciences brand, provides insights and industry updates critical to manufacturers of dietary supplements, healthy foods, and nutritious beverages. Nutritional Outlook keeps industry abreast of current market trends, research updates, news, and regulatory developments. Nutritional Outlook goes beyond the 24-hour news cycle and provides in-depth analysis to help industry players navigate the challenges and changes in the near- and long-term. Nutritional Outlook is a brand of MJH Life Sciences, the largest privately held, independent, full-service medical media company in North America, dedicated to delivering trusted health care news across multiple channels.

Eriomin is a patent-pending standardized extract from lemons containing the key flavonoid eriocitrin as well as other flavonoids.

Eriomin is a new citrus flavonoid ingredient recently introduced by Ingredients by Nature (Montclair, CA) that is designed to help manage prediabetes conditions by supporting glycemic control and reducing systemic inflammation and oxidative stress. Eriomin is a patent-pending standardized extract from lemons containing the key flavonoid eriocitrin as well as other flavonoids.

In a study recently published in Phytotherapy Research1, researchers determined that “short-term intervention with Eriomin, at doses of 200, 400, and 800 mg/day, benefited glycemic control, reduced systemic inflammation and oxidative stress, and reversed the prediabetic condition in 24% of the evaluated patients.” The 12-week study included 103 prediabetes patients.

“This Eriomin study is the first-of-its-kind human clinical trial to study the effects of eriocitrin and other lemon flavonoids for three significant and interconnected prediabetic factors: blood-glucose levels, oxidative stress, and inflammation,” said one of the study’s coauthors, Thais Cesar, PhD, associate professor of nutrition at Sao Paulo State University, in a press release. Following the success of the first study, the researchers began a second clinical trial, which is expected to yield results by the end of this year, she added.

References:

  1. Ribeiro CB et al. “Effectiveness of Eriomin in managing hyperglycemia and reversal of prediabetes condition: a double-blind, randomized, controlled study.” Phytotherapy Research. Published online ahead of print June 11, 2019.